AI tool to spot and reduce missed doses of oral medicines for Non-Hodgkin lymphoma patients
Official title: AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients, Integrating the Complete Care Pathway and an Interoperable Clinical Interface With Algorithms Paired With Explainability Tools.
Run by Grand Hôpital de Charleroi · NCT07546188 · Data updated 2026-11-12
This project will try an AI-based system to detect early risks of not taking prescribed oral treatments and alert clinicians for adults with Non-Hodgkin lymphoma treated at Grand Hôpital de Charleroi.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | Grand Hôpital de Charleroi Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Charleroi, Hainaut) |
| Status | Recruiting |
| Started | February 15, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | February 15, 2029 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT07546188 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) treated for Non-Hodgkin lymphoma in the Haematology Department at Grand Hôpital de Charleroi from November 2025 onward who can give informed consent are eligible.
✕Probably not a fit
Patients not treated at the center, those not taking oral prophylactic or targeted therapies, or those without sufficient clinical/dispensing data or capacity to consent are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project uses retrospective and prospective patient data from the Haematology Department to train and test machine learning models that predict non-adherence to oral therapies. It combines clinical variables, dispensing history, lab results, and drug interaction data with supervised algorithms and neural networks to identify patients at risk. The system will produce real-time alerts and tailored recommendations for physicians and coordinating nurses, supported by an intuitive interface that shows adherence trends. A multidisciplinary team including hematologists, advanced practice nurses, data scientists and patient partners will validate the tool in routine care.
Why it matters
Potential benefit: If successful, the tool could reduce missed doses, lower the risk of treatment failure and severe infections, and shorten hospital stays by triggering timely, targeted support.
How similar studies have gone: Digital adherence programs in other chronic conditions have shown encouraging but mixed results, while AI-driven, real-world predictive tools for oral oncology adherence remain relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients aged 18 and over who are treated in the Haematology Department at the Grand Hôpital de Charleroi from November 2025 onwards * Treated for a lymphoma, Non Hodgkin * Capable of giving informed consent Exclusion Criteria: * All other patients who did not meet the eligibility criteria
Where it's running
-
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium Recruiting
Study contacts
- Principal investigator: Marie Detrait, MD, PhD — Grand Hôpital de Charleroi
- Study coordinator: Marie Detrait, MD, PhD
- Email: marie.detrait@ghdc.be
- Phone: 0032 60 11 20 08
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
JMBI-001 in MYC-Positive Advanced Cancers
This study tests JMBI-001 to see if it is safe and tolerable for adults with MYC-positive advanced cancers.
-
UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas
A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.
-
Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma
This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.
-
GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma
We’re testing whether GSK5926371 is safe and can show activity in adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatment.
-
MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma
This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.
-
Electronic mindfulness-based music therapy for patients receiving stem cell transplantation
This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.